Copertina

Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kristofer G. Taylor, Bjarne Johannessen, Ian G. Mills, Morten B. Rye, Karol Axcrona, Rolf I. Skotheim
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer
di: Jun Lu, et al.
Pubblicazione: (2026)

Spatial Characteristics of Intraductal Carcinoma of the Prostate
di: Rodolphe Dupuis, et al.
Pubblicazione: (2025)

Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer
di: Marina Nasrin Sharifi, et al.
Pubblicazione: (2025)

Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single‐Institution Pilot Study
di: Cameron J. Britton, et al.
Pubblicazione: (2025)

miRNAs Regulating GSTP1 as Potential Diagnostic Biomarkers in Prostate Cancer
di: Shiv Verma, et al.
Pubblicazione: (2025)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
di: Eli Marie Grindedal, et al.
Pubblicazione: (2024)

Spatial Distribution of Prostate Cancer Missed by MRI‐Targeted Biopsy, Effect of a Perilesional Template, and Restaging in a Radical Prostatectomy Cohort
di: Ruth Himmelsbach, et al.
Pubblicazione: (2026)

In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines
di: Ana Laura Gómez-Rosas, et al.
Pubblicazione: (2026)

Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
di: Muhammet Bekir Hacioglu, et al.
Pubblicazione: (2025)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
di: Elizabeth Robinson, et al.
Pubblicazione: (2025)

Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis
di: Marco Oderda, et al.
Pubblicazione: (2024)

Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation
di: Liang G. Qu, et al.
Pubblicazione: (2025)

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
di: Tatsuya Shimomura, et al.
Pubblicazione: (2026)

Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer
di: Yu‐Hsiang Lin, et al.
Pubblicazione: (2025)

Evidence and Rationale for Prostate Cancer Screening
di: Takeshi Takahashi
Pubblicazione: (2025)

Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo‐Controlled, Biomarker‐Enriched Trial in Patients With the SOD2 Ala/Ala Variant
di: A. Mandl, et al.
Pubblicazione: (2025)

Castration Resistance Accelerates Prostate Cancer Kinetics
di: Sheila Jonnatan, et al.
Pubblicazione: (2026)

Altered Glycosylation of PSA in Prostate Cancer Tissue
di: Hannu Koistinen, et al.
Pubblicazione: (2025)

CHARGE: The “Big Questions” in Prostate Cancer for 2024
di: Andrea K. Miyahira, et al.
Pubblicazione: (2024)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
di: Christian P. Pavlovich, et al.
Pubblicazione: (2025)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
di: Yifu Shi, et al.
Pubblicazione: (2025)

Comments on the Study “Evaluating the Efficacy of Barley Water in Alleviating Radiotherapy‐Induced Dysuria in Prostate Cancer Patients”
di: Leibo Wang, et al.
Pubblicazione: (2026)

Developments in Ultrasound‐Based Imaging for Prostate Cancer Detection
di: Reid Vassallo, et al.
Pubblicazione: (2025)

Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core
di: Erum Z. Whyne, et al.
Pubblicazione: (2025)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
di: Takanori Tokunaga, et al.
Pubblicazione: (2025)

Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms
di: Charly Bâcle, et al.
Pubblicazione: (2025)

The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models
di: Haotian Chen, et al.
Pubblicazione: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2025)

Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients
di: Cem Onal, et al.
Pubblicazione: (2024)

Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment
di: Muhammad Umair, et al.
Pubblicazione: (2026)

Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
di: Christian Andrés Martínez Osorio, et al.
Pubblicazione: (2025)

Evaluating Local Doses for Prostate Cancer Treatment Using Low‐Dose‐Rate Brachytherapy Considering Oncological Control and Toxicity
di: Yasushi Nakai, et al.
Pubblicazione: (2025)

The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer
di: Trevor C. Hunt, et al.
Pubblicazione: (2025)

The 30th Annual Prostate Cancer Foundation Scientific Retreat Report
di: Andrea K. Miyahira, et al.
Pubblicazione: (2024)

Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer
di: Marta Victoria Lorenzo‐Sánchez, et al.
Pubblicazione: (2025)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
di: Anwar E. Ahmed, et al.
Pubblicazione: (2025)

Enhancing Prostate Cancer Diagnosis: The Combined Value of PHI and mpMRI
di: Y. M. Yáñez‐Castillo, et al.
Pubblicazione: (2025)

Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer
di: Anna‐Lena Lemster, et al.
Pubblicazione: (2025)

Role of Cell‐Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2‐ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance
di: Marco Oderda, et al.
Pubblicazione: (2025)

Evaluating the Efficacy of Barley Water in Alleviating Radiotherapy‐Induced Dysuria in Prostate Cancer Patients: A Randomized Placebo‐Controlled Trial
di: Vida Nazari, et al.
Pubblicazione: (2025)